Study guide
8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule
Oregon Multistate Pharmacy Jurisprudence Examination MPJE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Oregon Legal Framework
1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy
2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities
2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection
3 Chapter 3: Pharmacy Technicians, Interns & Preceptors
3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision
4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners
4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)
5 Chapter 5: Prescriber Authority & Prescription Requirements
5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags
6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority
6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine
7 Chapter 7: Counseling, Language Access & Confidentiality
7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy
8 Chapter 8: The Dispensing Process
8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse
9 Chapter 9: Nonprescription & Restricted Products
9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others
10 Chapter 10: Product Selection: Generic & Biologic Substitution
10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)
11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting
11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles
12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings
12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies
13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice
13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks
8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule
Key Takeaways Explain This Topic AI
Under OAR 855-041-1145, an Oregon pharmacy must dispense every prescription in a new container that complies with the PPPA (16 CFR 1700–1702), so containers are not reused.
Under the PPPA, a patient may make a blanket request for non-child-resistant packaging, but a prescriber's request covers only that specific prescription.
PPPA exemptions include sublingual nitroglycerin, isosorbide dinitrate 10 mg or less, mnemonic-pack contraceptives, methylprednisolone of 84 mg or less per package and prednisone of 105 mg or less per package.
CPSC testing requires at least 80% of children aged 42–51 months to be unable to open a package and at least 90% of adults aged 50–70 to open and re-close it.
PPPA exemptions are tied to the package: a vial of tablets that exceeds the exemption limit needs a child-resistant closure.
Last updated: October 2026
Why this matters
Area 3.6 covers packaging of dispensed drugs. The core federal law is the Poison Prevention Packaging Act of 1970 (PPPA) , enforced by the Consumer Product Safety Commission (CPSC) under 16 CFR 1700–1702 . Oregon adopts it by reference and adds a new-container requirement (OAR 855-041-1145).
Oregon's container rule (OAR 855-041-1145)
Each pharmacy must dispense a drug in a new container that complies with the PPPA regulations in 16 CFR 1700, 1701 and 1702 (v. 01/01/2025). In Oregon, prescription containers are not reused . A refill goes into a new container even if the patient brings back a clean vial.
What the PPPA requires
Oral prescription drugs for human use, and many household substances, must be dispensed in special (child-resistant) packaging unless an exemption or waiver applies. Under the CPSC test protocol (16 CFR 1700.20):
Child test: with a panel of children 42–51 months old , at least 85% must be unable to open the package in the first 5 minutes, and at least 80% after a demonstration in the next 5 minutes.
Senior-adult test: with adults 50–70 years old , at least 90% must be able to open and properly re-close the package within 5 minutes.
Waivers
Who Scope
Patient (or agent) May request non-child-resistant packaging for one prescription or all prescriptions (a blanket request). Pharmacies document it
Prescriber May request non-child-resistant packaging only for that specific prescription . A prescriber cannot issue a blanket waiver for all of a patient's drugs
- Pharmacist Cannot waive child-resistant packaging on their own initiative
- Exemptions commonly tested (16 CFR 1700.14)
Sublingual nitroglycerin .
Sublingual and chewable isosorbide dinitrate in strengths of 10 mg or less .
Oral contraceptives , conjugated estrogens and norethindrone acetate in mnemonic (calendar) dispenser packages , within the CPSC quantity limits.
Methylprednisolone tablets, no more than 84 mg per package.
Prednisone tablets, no more than 105 mg per package.
Betamethasone tablets, no more than 12.6 mg per package.
Mebendazole tablets, no more than 600 mg per package.
Sodium fluoride products, no more than 264 mg per package.
Potassium supplements in unit-dose forms, no more than 50 mEq per unit dose.
Anhydrous cholestyramine and colestipol powders.
Erythromycin ethylsuccinate granules and tablets, within the package limits.
Pancrelipase preparations and sacrosidase solution.
Aerosol products for inhalation.
Exemptions are tied to the package . A methylprednisolone dose pack of 21 × 4 mg (84 mg) is exempt. A 100-count bottle of 4 mg tablets dispensed in a vial is not.
Other packaging rules
Hospital inpatients receiving drugs administered by staff don't need special packaging. Drugs dispensed to patients for home use do.
Med paks (OAR 855-041-1140) must comply with the PPPA, or the patient must have waived child-resistant packaging, and must use Class B containers.
Repackaged drugs must use USP-compliant containers (OAR 855-041-1135).
Unit-dose packaging may omit the physical description on the label (OAR 855-041-1130(12)), but PPPA rules still apply to drugs dispensed for home use.
Light- and moisture-sensitive drugs must be packaged as the manufacturer or USP specifies (OAR 855-041-1036).
Nonprescription drugs
Many OTC drugs also need special packaging, such as aspirin, acetaminophen, iron-containing products and diphenhydramine. A manufacturer of an OTC product subject to the PPPA may market one size in non-child-resistant packaging if it is conspicuously labeled "This package for households without young children" and the product is also available in child-resistant packaging. Section 9.1 covers OTC labeling.
Documenting waivers in practice
PPPA waivers are easiest to defend when they are documented. Oregon doesn't prescribe a waiver form, but good practice and most inspection expectations follow this pattern:
Record who asked. Note in the patient profile that a blanket request came from the patient or agent, or that the prescriber requested non-child-resistant packaging for a particular prescription.
Record the scope. A patient's request may cover all prescriptions or only some. A prescriber's request covers only the prescription, and its refills, on which it appears.
Revisit it when circumstances change. If a grandchild moves into the home, counsel the patient that child-resistant packaging can be restored at any time.
Check the technology. Pharmacy software that defaults to easy-open caps for a patient must reflect an actual request from the patient. A system setting is not a waiver.
The pharmacist remains responsible for the finished prescription, including its container. That holds even when a technician performs final product verification, because the pharmacist still verifies the label and the other elements beyond the drug-and-dose match (OAR 855-115-0130(3)).
Important
A prescriber's checkbox saying "all future prescriptions in easy-open caps" does not create a blanket waiver. Only the patient may make a blanket request. The prescriber's request covers the specific prescription.
Exam scenario
An 82-year-old with severe arthritis receives four new prescriptions:
Prednisone 10 mg #30.
Sublingual nitroglycerin.
A methylprednisolone 4 mg dose pack.
Atorvastatin.
She asks for easy-open caps on everything. With her request , all four may be dispensed in non-child-resistant packaging, and the pharmacy records her blanket request. Without it , nitroglycerin SL and the 84 mg dose pack are exempt. Prednisone 10 mg #30 (300 mg) exceeds the 105 mg exemption, so it needs a child-resistant closure, and so does atorvastatin . Each must go in a new container.